Bert Vogelstein
Fondateur chez Thrive Earlier Detection Corp.
Profil
Bert Vogelstein is the founder of Thrive Earlier Detection Corp.
(founded in 2019) and Haystack Oncology, Inc. (founded in 2021).
He holds the title of Scientific Advisory Board at Thrive Earlier Detection Corp.
Currently, Dr. Vogelstein is a member of the Scientific Advisory Board at Cage Pharma, Inc. and a Venture Partner at Catalio Capital Management LP.
Dr. Vogelstein is also the founder of EXACT Sciences Corp., Personal Genome Diagnostics, Inc., Sysmex Inostics, Inc...- Current job(s): Scientific Advisory Board at Cage Pharma, Inc., Venture Partner at Catalio Capital Management LP.
-.
Education history: Dr. Vogelstein completed his undergraduate degree at the University of Pennsylvania and obtained a doctorate degree from The Johns Hopkins University School of Medicine.
Postes actifs de Bert Vogelstein
| Sociétés | Poste | Début |
|---|---|---|
Thrive Earlier Detection Corp.
 Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Fondateur | 01/01/2019 |
Sysmex Inostics, Inc.
 Sysmex Inostics, Inc. Medical/Nursing ServicesHealth Services Part of Sysmex Corp., Sysmex Inostics, Inc. provides mutation testing, companion diagnostics development and other diagnostic services. The company is based in Baltimore, MD. The company was founded by Luis A. Diaz, Bert Vogelstein. | Fondateur | - |
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Fondateur | - |
Cage Pharma, Inc.
 Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cage Pharma, Inc. operates as a developmental stage bio-pharmaceutical company. It focuses on developing anti-cancer drugs. The company was founded on October 24, 2008 by Jean–Francois H. Geschwind and is headquartered in Potomac, MD. | Consultant / Advisor | - |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Private Equity Investor | - |
Haystack Oncology, Inc.
 Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Fondateur | 01/01/2021 |
Anciens postes connus de Bert Vogelstein
| Sociétés | Poste | Fin |
|---|---|---|
| EXACT SCIENCES CORPORATION | Fondateur | - |
Formation de Bert Vogelstein
| University of Pennsylvania | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EXACT SCIENCES CORPORATION | Health Technology |
| Entreprise privées | 6 |
|---|---|
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Health Technology |
Sysmex Inostics, Inc.
Sysmex Inostics, Inc. Medical/Nursing ServicesHealth Services Part of Sysmex Corp., Sysmex Inostics, Inc. provides mutation testing, companion diagnostics development and other diagnostic services. The company is based in Baltimore, MD. The company was founded by Luis A. Diaz, Bert Vogelstein. | Health Services |
Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
Cage Pharma, Inc.
Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cage Pharma, Inc. operates as a developmental stage bio-pharmaceutical company. It focuses on developing anti-cancer drugs. The company was founded on October 24, 2008 by Jean–Francois H. Geschwind and is headquartered in Potomac, MD. | Health Technology |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Finance |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Health Services |
